Citicoline (Cdp-Choline) for Neuroprotection

Research suggests that citicoline may exert neuroprotective effects through several distinct biological mechanisms, with animal and human studies generally pointing in a supportive direction. Two rodent studies indicate that citicoline reduces brain injury following ischemia by upregulating the protective protein SIRT1 and by limiting the activity of the membrane-degrading enzyme phospholipase A2 while also curbing the production of harmful free radicals, with the SIRT1 findings notably demonstrating that the protective effect disappears when that protein is blocked or absent. A small clinical study in ischemic stroke patients found that intravenous citicoline was associated with meaningful reductions in blood-based markers of neuronal and glial damage compared to standard care alone, offering some translational support for the animal findings. However, the body of evidence reviewed here is limited in scope, consisting of preclinical animal models and a single human study rather than large randomized controlled trials, so while the mechanistic picture is becoming clearer, the overall clinical evidence base remains preliminary and should be interpreted with appropriate caution.